Hana Pharm Co., Ltd. (KRX: 293480)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,920
+70 (0.65%)
Dec 20, 2024, 3:30 PM KST

Hana Pharm Statistics

Total Valuation

Hana Pharm has a market cap or net worth of KRW 194.08 billion.

Market Cap 194.08B
Enterprise Value n/a

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date Mar 14, 2025
Ex-Dividend Date n/a

Share Statistics

Hana Pharm has 17.77 million shares outstanding.

Current Share Class n/a
Shares Outstanding 17.77M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 57.71%
Owned by Institutions (%) 0.65%
Float 7.06M

Valuation Ratios

The trailing PE ratio is 4.87.

PE Ratio 4.87
Forward PE n/a
PS Ratio 0.85
PB Ratio 1.46
P/TBV Ratio 2.50
P/FCF Ratio 12.78
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.36.

Current Ratio 1.63
Quick Ratio 1.22
Debt / Equity 0.36
Debt / EBITDA 0.82
Debt / FCF 1.91
Interest Coverage 30.47

Financial Efficiency

Return on equity (ROE) is 35.53% and return on invested capital (ROIC) is 20.21%.

Return on Equity (ROE) 35.53%
Return on Assets (ROA) 15.52%
Return on Capital (ROIC) 20.21%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover 1.09
Inventory Turnover 2.43

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.78% in the last 52 weeks. The beta is 0.47, so Hana Pharm's price volatility has been lower than the market average.

Beta (5Y) 0.47
52-Week Price Change -21.78%
50-Day Moving Average 10,975.20
200-Day Moving Average 12,232.95
Relative Strength Index (RSI) 51.35
Average Volume (20 Days) 24,389

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Hana Pharm had revenue of KRW 139.33 billion and earned 24.30 billion in profits. Earnings per share was 2,243.00.

Revenue 139.33B
Gross Profit 94.00B
Operating Income 31.81B
Pretax Income 30.96B
Net Income 24.30B
EBITDA 35.33B
EBIT 31.81B
Earnings Per Share (EPS) 2,243.00
Full Income Statement

Balance Sheet

The company has 16.49 billion in cash and 29.05 billion in debt, giving a net cash position of -12.56 billion or -706.42 per share.

Cash & Cash Equivalents 16.49B
Total Debt 29.05B
Net Cash -12.56B
Net Cash Per Share -706.42
Equity (Book Value) 81.30B
Book Value Per Share 7,469.67
Working Capital 30.69B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 25.38 billion and capital expenditures -10.19 billion, giving a free cash flow of 15.19 billion.

Operating Cash Flow 25.38B
Capital Expenditures -10.19B
Free Cash Flow 15.19B
FCF Per Share 854.50
Full Cash Flow Statement

Margins

Gross margin is 67.47%, with operating and profit margins of 22.83% and 17.44%.

Gross Margin 67.47%
Operating Margin 22.83%
Pretax Margin 22.22%
Profit Margin 17.44%
EBITDA Margin 25.36%
EBIT Margin 22.83%
FCF Margin 10.90%

Dividends & Yields

Hana Pharm does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio 4.21%
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield 20.54%
FCF Yield 7.83%
Dividend Details

Stock Splits

The last stock split was on April 28, 2021. It was a forward split with a ratio of 1.1000011.

Last Split Date Apr 28, 2021
Split Type Forward
Split Ratio 1.1000011

Scores

Hana Pharm has an Altman Z-Score of 2.67. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.67
Piotroski F-Score n/a